Results 11 to 20 of about 30,317 (268)
Vaccines against Meningococcal Diseases [PDF]
Microorganisms, 2020 Neisseria meningitidis is the main cause of meningitis and sepsis, potentially life-threatening conditions. Thanks to advancements in vaccine development, vaccines are now available for five out of six meningococcal disease-causing serogroups (A, B, C, W,
Mariagrazia Pizza +2 more
doaj +3 more sources
Clonal analysis of meningococci during a 26 year period prior to the introduction of meningococcal serogroup C vaccines [PDF]
, 2015 Meningococcal disease remains a public health burden in the UK and elsewhere. Invasive Neisseria meningitidis, isolated in Scotland between 1972 and 1998, were characterised retrospectively to examine the serogroup and clonal structure of the circulating
Clarke, Stuart C. +3 more
core +23 more sources
Pediatric Drugs, 2004 Meningococcal disease is one of the most feared and serious infections in the young and its prevention by vaccination is an important goal. The high degree of antigenic variability of the organism makes the meningococcus a challenging target for vaccine prevention. Meningococcal polysaccharide vaccines against serogroup A and C are efficacious and have
Rüggeberg, J, Pollard, A
openaire +6 more sources
Meningococcal vaccines in China [PDF]
Human Vaccines & Immunotherapeutics, 2021 Meningococcal meningitis caused by Neisseria meningitidis is a reportable infectious disease in China, due to the high incidence of meningitis in the era before the availability of vaccines. The disease incidence was markedly reduced after meningococcal vaccination was introduced in the 1980s.
Shanshan Wang +5 more
openaire +4 more sources
Meningococcal Vaccinations [PDF]
Infectious Diseases and Therapy, 2016 Neisseria meningitidis, a gram-negative diplococcal bacterium, is a common asymptomatic nasopharyngeal colonizer that may infrequently lead to invasive disease in the form of meningitis or bacteremia. Six serogroups (A, B, C, W, X and Y) are responsible for the majority of invasive infections.
Eva Sullivan, Nancy F. Crum-Cianflone
openaire +2 more sources
Meningococcal Vaccine Trials [PDF]
, 2003 The evaluation of meningococcal vaccines in humans is a challenging task. Issues of safety, and benefit to the individual patient and to the community may raise difficult ethical problems. The inherent variability of human responses, the rarity of clinical disease, age-dependence in the immune response, and the role of carriers complicates the ...
Paddy Farrington, Elizabeth Miller
openalex +4 more sources
Expert Review of Vaccines, 2002 The successful introduction of a protein-polysaccharide conjugate vaccine against serogroup C meningococci into the UK infant immunization schedule, in combination with a catch-up campaign for individuals less than 18 years of age, has seen virtually all group C disease eliminated in childhood.
Bethell, D, Pollard, A
openaire +5 more sources
Meningococcal glycoconjugate vaccines [PDF]
Human Vaccines, 2011 Neisseria meningitidis is a major cause of invasive bacterial infections worldwide. For this reason, efforts to control the disease have been directed at optimizing meningococcal vaccines and implementing appropriate vaccination policies. In the past, plain polysaccharide vaccines containing purified capsular polysaccharides A, C, Y and W135 were ...
GASPARINI, ROBERTO, PANATTO, DONATELLA
openaire +3 more sources
Meningococcal vaccination in pregnancy [PDF]
Human Vaccines & Immunotherapeutics, 2018 Invasive meningococcal disease causes meningitis and septicemia worldwide with highest rates of disease occurring in children
Manish Sadarangani +2 more
openaire +4 more sources